Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

CHD rates decrease significantly in the U.S.

Significant improvements seen across multiple sociodemographic groups, according to a new study in the American Journal of Preventive Medicine

15 Jun 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

Smoking linked to worsening degenerative disc disease in cervical spine

Adding to the already length list of reasons not to smoke, researchers have connected smoking to worsening degenerative disc disease in the cervical spine, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif.

18 Feb 2016

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels.

8 Feb 2016

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.

9 Nov 2015

Bariatric surgery results in substantial weight loss in overweight children with Prader-Willi syndrome

Obesity is a leading cause of complications and death in children suffering from Prader-Willi syndrome (PWS), yet there are few effective treatment options for these patients. In a new study published in Surgery for Obesity and Related Disease researchers found that bariatric surgery, specifically laparoscopic sleeve gastrectomy (LSG), resulted in substantial weight loss with no apparent adverse effect on growth in a small group of severely overweight patients with PWS.

29 Sep 2015

Reducing SSB intake among children and adolescents associated with greater increase in HDL-C

In the first study to investigate blood lipid levels in association with consumption of sugar-sweetened beverages (SSBs) in a racially and ethnically diverse sample of Boston area schoolchildren, researchers found there was an inverse association between SSB intake changes and HDL-cholesterol increases (HDL-C is the "good cholesterol").

3 Sep 2015

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal.

2 Sep 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Inflammation from diets deficient in nutrients contribute to weight despite intake of macronutrients

If you are watching what you eat, working out, and still not seeing improvements in your cholesterol, blood pressure, blood sugar, etc., here's some hope. A new report appearing in the August 2015 issue of The FASEB Journal suggests that inflammation induced by deficiencies in vitamins and minerals might be the culprit.

6 Aug 2015

Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training in the gym leads to a fall in liver fat levels. This is the finding of a new study held at the University of Haifa in cooperation with Tel Aviv Medical Center and Tel Aviv University.

28 Jul 2015

TSRI scientists awarded grant to explore therapeutic potential of protein receptors in Parkinson's disease, other disorders

Scientists from the Florida campus of The Scripps Research Institute have been awarded nearly $1.5 million from the National Institute of General Medical Sciences of the National Institutes of Health to explore the therapeutic potential of a class of proteins that play essential roles in the regulation and maintenance of human health.

28 Jul 2015

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.

24 Jul 2015

$Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients$

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

End-stage renal disease (ERSD) is the last stage of chronic kidney disease where the kidneys function at under 10 to 15 percent of their normal capacity. At this stage, kidneys cannot effectively remove waste or excess fluid from the blood system, and dialysis or a kidney transplant is necessary to live.

14 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

Study: Genes may not trigger heart disease in people suffering from migraine with aura

A new study suggests that genes may not be to blame for the increased risk of heart disease some studies have shown in people with migraine, especially those with migraine with aura. The research is published during Headache/Migraine Awareness Month in the inaugural issue of the journal Neurology Genetics, an open access, or free to the public, online-only, peer-reviewed journal from the American Academy of Neurology.

3 Jul 2015